TITLE

Preoperative Chemotherapy and the Outcome of Liver Resection for Colorectal Metastases

AUTHOR(S)
Hewes, J. C.; Dighe, S.; Morris, R. W.; Hutchins, R. R.; Bhattacharya, S.; Davidson, B. R.
PUB. DATE
February 2007
SOURCE
World Journal of Surgery;Feb2007, Vol. 31 Issue 2, p353
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Neoadjuvant systemic chemotherapy is being increasingly used prior to liver resection for colorectal metastases. Oxaliplatin has been implicated in causing structural changes to the liver parenchyma, and such changes may increase the morbidity and mortality of surgery. A retrospective study was undertaken of 101 consecutive patients who had undergone liver resection for colorectal metastases in two HPB centers. Preoperative demographic and premorbid data were gathered along with liver function tests and tumor markers. A subjective assessment of the surgical procedure was noted, and in-hospital morbidity and mortality were calculated. The effect of preoperative chemotherapy on short-term and long-term outcome was analyzed, and actuarial 1 and 3 year survival was determined. Patients who received neoadjuvant chemotherapy had a higher number of metastases (median 2, range 1–8 versus median 1, range 1–5; P = 0.019) and more had synchronous tumors (24 patients versus 8; P < 0.001). Overall morbidity was 37% and hospital mortality was 3.9%. Operative and in-hospital outcome was not influenced by chemotherapy. Long-term survival was worse in patients who had received preoperative chemotherapy (actuarial 3-year survival 62% versus 80%; P = 0.04). This study shows no evidence that neoadjuvant chemotherapy, and in particular oxaliplatin, increases the risk associated with liver resection for colorectal metastases. Long-term outcome is reduced in patients receiving preoperative chemotherapy, although they have more advanced disease.
ACCESSION #
23819168

 

Related Articles

  • 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. Sugiyama, Masahiro; Sakahara, Harumi; Torizuka, Tatsuo; Kanno, Toshihiko; Nakamura, Fumitoshi; Futatsubashi, Masami; Nakamura, Satoshi // Journal of Gastroenterology;2004, Vol. 39 Issue 10, p961 

    Background. Positron emission tomography (PET) with 18F-fluoro-2-deoxy-d-glucose (18F-FDG) is useful in detecting distant metastases from a variety of malignancies. However, its efficiency in detecting distant metastases from hepatocellular carcinoma (HCC) has not been investigated. The aim of...

  • Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease. Pang, Jack X. Q.; Zimmer, Scott; Niu, Sophia; Crotty, Pam; Tracey, Jenna; Pradhan, Faruq; Shaheen, Abdel Aziz M.; Coffin, Carla S.; Heitman, Steven J.; Kaplan, Gilaad G.; Swain, Mark G.; Myers, Robert P. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Background: Liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) is a validated method for noninvasively staging liver fibrosis. Most hepatic complications occur in patients with advanced fibrosis. Our objective was to determine the ability of LSM by TE to predict hepatic...

  • Adrenalectomy for metastases from hepatocellular carcinoma—a single center experience. Popescu, Irinel; Alexandrescu, Sorin; Ciurea, Silviu; Brasoveanu, Vlad; Hrehoret, Doina; Gangone, Eliza; Boros, Mirela; Herlea, Vlad; Croitoru, Adina // Langenbeck's Archives of Surgery;Jul2007, Vol. 392 Issue 3, p381 

    Adrenal metastases (AM) from hepatocellular carcinoma (HCC) are rarely seen in clinical practice. The treatment is not standardized, the indications and efficacy of different therapeutic approaches being still controversial. Between January 1995 and December 2005, 174 patients underwent liver...

  • Manual lymph drainage in patients with tumoral activity. Flor, Esther Mena; Flor, Enriqueta Mena; Flor, Alfredo Mena // Journal of Phlebology & Lymphology;2009, Vol. 2, p13 

    Evidence supports the use of complex decongestive physiotherapy in cases of cancer-related lymphedema, despite the possibility of tumor recurrence due to this therapy 1. An increase of tumor recurrence resulting from lymphedema therapy is controversial. The aim of the current study was to...

  • Expression of multidrug resistance protein in metastatic colorectal carcinomas. Nanashima, Atsushi; Yamaguchi, Hiroyuki; Matsuo, Seiji; Sumida, Yorihisa; Tsuji, Takashi; Sawai, Terumitsu; Yasutake, Toru; Nakagoe, Tohru; Ayabe, Hiroyoshi; Nanashima, A; Yamaguchi, H; Matsuo, S; Sumida, Y; Tsuji, T; Sawai, T; Yasutake, T; Nakagoe, T; Ayabe, H // Journal of Gastroenterology;1999, Vol. 34 Issue 5, p582 

    To clarify the relationship between multidrug resistance protein (MRP) and clinicopathologic features, the influence of adjuvant chemotherapy, and prognosis of patients who underwent resection of metastatic liver carcinomas originating from colorectal carcinomas, we examined the expression of...

  • What's Old Is New Again: Patients Receiving Hepatic Arterial Infusion Chemotherapy. Barber, Fedricker Diane; Fabugais-Nazario, Lou Ellen // Clinical Journal of Oncology Nursing;Nov/Dec2003, Vol. 7 Issue 6, p647 

    Discusses the use of hepatic arterial infusion (HAI) chemotherapy in hepatocellular carcinoma or metastatic liver disease. Cause of the increased frequency of the liver as the initial site of metastasis; Methods used to deliver HAI chemotherapy; Complications associated with HAI chemotherapy;...

  • The Role of Radiofrequency Ablation in Multiple Liver Metastases to Debulk the Tumor: A Pilot Study before Alternative Therapies. Frezza, Eldo E.; Wachtel, Mitchell S.; Barragan, Barnard; Chiriva-Internati, Maurizio; Cobos, Everardo // Journal of Laparoendoscopic & Advanced Surgical Techniques;Jun2007, Vol. 17 Issue 3, p282 

    Introduction: In this study, our aim was to proceed with the first study of our patients by evaluating different metastatic tumor to the liver to check whether, after debulking the tumor with radiofrequency ablation (RFA), the chemotherapy, could increase the survival in these patients as a...

  • Circulating biomarkers in hepatocellular carcinoma. Morris, Karen; Tugwood, Jonathan; Khoja, Leila; Lancashire, Matthew; Sloane, Robert; Burt, Debbie; Shenjere, Patrick; Zhou, Cong; Hodgson, Clare; Ohtomo, Toshihiko; Katoh, Atsuhiko; Ishiguro, Takahiro; Valle, Juan; Dive, Caroline // Cancer Chemotherapy & Pharmacology;Aug2014, Vol. 74 Issue 2, p323 

    Purpose: Our aims are to determine levels of circulating cellular and protein biomarkers in hepatocellular carcinoma (HCC) patients and to analyse any relationships with clinical parameters. Methods: Fifty-four consenting patients were recruited. Circulating tumour cells (CTCs) were enumerated...

  • Bone metastasis in hepatocellular carcinoma: Need for reappraisal of treatment. Suresh Attili, V. Satya; Babu, K. Govind; Lokanatha, D.; Bapsy, P. P.; Ramachandra, C.; Rajshekar, H. // Journal of Cancer Research & Therapeutics;Apr-Jun2008, Vol. 4 Issue 2, p93 

    Bone is an uncommon site of metastasis in patients with hepatocellular carcinoma (HCC), and often overlooked. We report two cases that had isolated bone metastasis; one of them had prolonged disease-free survival. The present series, along with the literature review, reinforces the idea that HCC...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics